Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | USP8 | P40818 | 1/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.34 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30281224 | 1.00 | KDM4E (0.40) | KDM4EALDH1A1CA1CA2CA7 | |
| Water SCHEMBL31616949 | 0.98 | KDM4E (0.39) | KDM4EALDH1A1CA1CA2CA7 | |
| SCHEMBL6686429 | 0.89 | ACHE (0.47) | KDM4EALDH1A1CA1CA2CA7 | |
| SCHEMBL17338043 | 0.87 | ACHE (0.44) | KDM4EALDH1A1CA1CA7CA9 | |
| SCHEMBL31511963 | 0.87 | HPGD (0.38) | ALDH1A1HPGDMAPTGAA | |
| SCHEMBL28393372 | 0.83 | CHEK1 (0.38) | KDM4EALDH1A1MAPTUSP8USP7 | |
| SCHEMBL4475236 | 0.83 | CTSV (0.45) | ALDH1A1HPGDKMT2AMEN1MAPT | |
| SCHEMBL1546879 | 0.83 | CTSV (0.45) | ALDH1A1HPGDKMT2AMEN1MAPT | |
| SCHEMBL31401846 | 0.76 | PDE3B (0.46) | KDM4EALDH1A1CA1CA2CA7 | |
| SCHEMBL26841070 | 0.76 | PDE3B (0.46) | KDM4EALDH1A1CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532116-B | Synthesis method of anti-tumor targeted therapeutic drug tivozanib | WUHAN MAIDESEN MEDICAL TECHNOLOGY CO LTD | 2015-01-21 | — | — | CN | claimed |
| CN-102532116-A | Synthesis method of anti-tumor targeted therapeutic drug tivozanib | WUHAN MAIDESEN MEDICAL TECHNOLOGY CO LTD | 2012-07-04 | — | — | CN | claimed |
| CN-102532116-B | Synthesis method of anti-tumor targeted therapeutic drug tivozanib | WUHAN MAIDESEN MEDICAL TECHNOLOGY CO LTD | 2015-01-21 | — | — | CN | disclosed |
| CN-102532116-A | Synthesis method of anti-tumor targeted therapeutic drug tivozanib | WUHAN MAIDESEN MEDICAL TECHNOLOGY CO LTD | 2012-07-04 | — | — | CN | disclosed |
| EP-1559715-B1 | N-{2-CHLORO-4-[(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL}-N'-(5-METHYL-3-ISOXAZOLYL)UREA SALT IN CRYSTALLINE FORM | KIRIN BREWERY (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-7166722-B2 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20060052415-A1 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1559715-A1 | N-[2-CHLORO-4-(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL]-N'-(5-METHYL-3-ISOXAZOLYL)UREA SALT IN CRYSTALLINE FORM | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-6897210-B2 | Quinazoline derivatives and pharmaceutical compositions containing them | ZENECA LIMITED (GB) | 2005-05-24 | — | — | US | disclosed |
| US-6809106-B1 | ANTIPROLIFERATION AGENTS; SUCH AS 4-(2-METHOXYPHENOXY)-ANILINO-3-CHLORO-6,7-DIMETHOXYQUINOLINE | ASTRAZENECA AB (SE) | 2004-10-26 | — | — | US | disclosed |
| EP-1178966-B1 | QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES | ASTRAZENECA AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-0990647-B1 | PROCESS FOR PRODUCING QUINOLONE DERIVATIVES | KIRIN BREWERY (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-1178966-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES | AstraZeneca AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| US-6187926-B1 | REACTING ORTHO-AMINOACETOPHENONE DERIVATIVE WITH FORMIC ACID ESTER IN APROTIC SOLVENT IN PRESENCE OF BASE, ADDING PROTIC SOLVENT TO REACTION MIXTURE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-02-13 | — | — | US | disclosed |
| WO-2000068200-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES | ASTRAZENECA AB (SE) | 2000-11-16 | — | — | WO | disclosed |
| EP-0990647-A1 | PROCESS FOR PRODUCING QUINOLONE DERIVATIVES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2000-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052415-A1 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form | UACA, REN, TPMT | KDM4E 420/4885ALDH1A1 3400/4885CA1 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.